English

Marketing and distribution agreement in Germany

Report this content
(Lysaker, Norway, 28 February 2007) Navamedic ASA has signed a marketing and distribution agreement with an undisclosed partner in the German market. With this agreement, the company has established a marketing and distribution network of 13 partners covering 25 countries.
During February, Navamedic has also received Marketing Authorisation (MA) for Glucomed®/Flexove(TM) in Germany. The product is not subject to reimbursement in Germany. With both marketing/distribution partner and MA in place, there are no further regulatory hurdles before Glucomed/Flexove can be launched in the German market. Glucomed/Flexove is the second pharmaceutical glucosamine product approved in the German market.


-Germany will be an important market for us, and we are happy to have secured a strong partner. Our partner is one of the leading players in the German pharma market and has strong experience from OTC branding. The German market is fragmented, with competition from pharmaceuticals as well as cost supplements, and a successful entry depends on market knowledge and strong marketing muscle. We have found a partner who has both, says CEO Øyvind Brekke in Navamedic.


The five- year agreement is non-exclusive. Nevertheless, the agreement imposes certain limitations on Navamedic's partner with respect to launching other glucosamine products. The agreement opens for re-branding of the product under the partner's own brand.


Navamedic will give more information regarding timing of launch of Glucomed/Flexove in Europe in the Q1-presentation on 25 April 2007.
 
For further information, please contact:


Øyvind W. Brekke, CEO Navamedic ASA
Office: +47 67 11 25 40
Mobile: +47 91 19 81 64


Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA
Office: +47 67 11 25 44
Mobile: +47 91 34 70 21
 
 
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. Navamedic`s product Glucomed®/Flexove(TM) has been approved across 25 EU/EEA states by European Medicines Agency (EMEA), as the first and only glucosamine based medicine against osteoarthritis.  The company`s products will be sold through a network of sales, marketing and distribution partners. For more information, please see www.navamedic.com

Subscribe